An Overview of PA-457

be-VEER-ih-mat

Other Name(s): BVM, PA 457, PA-457, PA457 cpd
Drug Class: Opportunistic Infection and Other Drugs

Bevirimat is a type of medicine called a maturation inhibitor. It is the first drug in this class to be studied for the treatment of HIV. Maturation inhibitors work by blocking viral maturation, a late step in HIV development that is needed for the virus to become infectious.

Indications and Usage

Bevirimat is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration

Bevirimat comes in tablet and liquid form and is taken by mouth. Current studies are mainly using the liquid form.

Recommended Daily Dose

Bevirimat has been studied at doses of 25 to 600 mg taken once daily in clinical trials.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, bevirimat may cause some unwanted effects. Only mild side effects, including diarrhea with other stomach problems, were seen during early trials. Further study is needed to identify possible side effects of bevirimat.

Drug Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

Click here to search ClinicalTrials.gov for trials that use PA-457.

Manufacturer Information

Bevirimat
Panacos Pharmaceuticals, Inc.
Corporate Headquarters
134 Coolidge Avenue
Watertown, MA 02472
Phone: 617-926-1551
Fax: 617-923-2245